TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting
On May 15, 2020, TG Therapeutics (NASDAQ: TGTX) announced that preclinical data for TG-1701, a selective BTK inhibitor, will be presented at the 2020 American Association for Cancer Research (AACR) annual meeting. The presentation, titled 'TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, does not inhibit anti-CD20-driven ADCC and ADCP in vitro,' will be available on demand starting June 22, 2020. TG Therapeutics is advancing multiple therapies for B-cell malignancies and autoimmune diseases and is currently in various clinical development phases.
- TG-1701 has been selected for presentation at a prominent AACR meeting, showcasing its preclinical data.
- TG Therapeutics is advancing a robust pipeline of therapies for hematological malignancies and autoimmune diseases.
- None.
NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that preclinical data for TG-1701, the Company’s highly selective, BTK inhibitor, has been selected for presentation at the upcoming 2020 American Association for Cancer Research (AACR) annual meeting, to be held virtually
The presentation details are as follows:
- Abstract Number: 2939
- Available on Demand: Monday, June 22, 2020 at 9:00 AM ET
- Session Title: Combination Immunotherapies 2
- Presenting Author: Gaël Roué, PhD, Lymphoma Translational Group leader, Josep Carreras Leukaemia Research Institute (IJC)
A copy of the above referenced abstract can be viewed online through the AACR meeting website at www.aacr.org. Following the presentation, the data presented will be available on the Publications page of the Company’s website at www.tgtherapeutics.com/publications.cfm.
ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon, which may lead to a differentiated safety profile. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.
Cautionary Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. For these statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause our actual results to differ materially. Factors that could cause such differences include: our ability to successfully and cost-effectively complete preclinical and clinical trials, including clinical trials of TG-1701 and our other pipeline candidates; the risk that the data (both safety and efficacy) from future clinical trials will not coincide with the data analyses from prior preclinical and clinical trials; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
CONTACT:
Jenna Bosco
Senior Vice President,
Corporate Communications
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com
FAQ
What is the purpose of the TG-1701 presentation at AACR 2020?
When will the TG-1701 data be available to the public?
What are the clinical development phases of TG Therapeutics' drugs?
What does the abstract for TG-1701 include?
What is the significance of the AACR annual meeting for TGX Therapeutics?
